natgillin/translations-raw huggingface dataset:
• Øvrige indholdsstoffer: calciumsilicat, croscarmellosenatrium, crospovidon, silicondioxid, xylitol, mikrokrystallinsk cellulose, aspartam, acesulfamkalium, vanillesmag (indeholder lactose), vinsyre, magnesiumstearat. 
• The other ingredients are calcium silicate, croscarmellose sodium, crospovidone, silicon dioxide, xylitol, microcrystalline cellulose, aspartame, acesulfame potassium, vanilla flavour (contains lactose), tartaric acid and magnesium stearate.
• Muskelstivhed, døsighed/søvnighed, langsom vejrtrækning, kvælningsfornemmelse, højt eller lavt blodtryk, unormal hjerterytme. 
• muscle stiffness, and drowsiness or sleepiness, slower breathing, choking, high or low blood pressure, abnormal rhythms of the heart.
ABILIFY er effektiv i dosisområdet 10 mg/dag til 30 mg/dag (dvs. 10 ml til 30 ml opløsning/dag). 
ABILIFY is effective in a dose range of 10 mg/day to 30 mg/day (i.e. 10 mL to 30 mL solution/day).
I kliniske forsøg havde en daglig oral dosis på 10 mg til 30 mg aripiprazol ingen signifikant effekt på metabolismen af CYP2D6-substrater (dextromethorphan/3-methoxymorphinan forholdet), CYP2C9 (warfarin), CYP2C19 (omeprazol) og CYP3A4 (dextromethorphan). 
In clinical studies, oral doses of 10 mg/day to 30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
I kliniske forsøg havde en daglig dosis på 10 mg til 30 mg aripiprazol ingen signifikant effekt på metabolismen af CYP2D6-substrater (dextromethorphan/3-methoxymorphinan forholdet), CYP2C9 (warfarin), CYP2C19 (omeprazol) og CYP3A4 (dextromethorphan). 
In clinical studies, 10 mg/day to 30 mg/day doses of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
Andelen af patienter, der gennemførte forsøget, var signifikant højere for patienter i behandling med oral aripiprazol (43 %) end med oral halperidol (30 %). 
The overall completion rate was significantly higher for patients on oral aripiprazole (43 %) than for oral haloperidol (30 %).
Bivirkningerne er opstillet efter systemorganklasse og hyppighed: meget almindelig (≥ 1/10), 
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to
ABILIFYs sikkerhed og virkning hos børn og unge i alderen 0 til 17 år er endnu ikke klarlagt. 
The safety and efficacy of ABILIFY solution for injection in children and adolescents aged 0 to 17 years have not been established.
Brug til børn og unge Den anbefalede dosis til unge er 10 ml opløsning (svarende til 10 mg aripiprazol) én gang dagligt. 
Use in children and adolescents The recommended dose for adolescents is 10 mL solution (corresponding to 10 mg aripiprazole)
• Aktivt stof: aripiprazol. 
• The active substance is aripiprazole.
• livstruende uregelmæssig hjerterytme, 
• life-threatening irregular heartbeat,
Diabetisk hyperosmolær koma Diabetisk ketoacidose 
Hyperprolactinaemia Diabetic hyperosmolar coma Diabetic ketoacidosis
• andre antidepressiva (fx venlafaxin og tryptophan) til behandling af svær depression 
• other anti-depressants (such as venlafaxine and tryptophan) used in major depression
ABILIFY indeholder aspartam 
ABILIFY contains aspartame
Hver æske indeholder ét type I-hætteglas til engangsbrug med gummibutylstopper og afrivelig aluminiumsforsegling. 
Each carton contains one single-use type I glass vial with a rubber butyl stopper and a "tear-off" aluminium seal.
Hvis du får ABILIFY, vil din læge drøfte med dig, om du bør amme dit barn, ved at se på fordelen for dig ved behandling og fordelen ved amning for barnet. 
If you are receiving ABILIFY, your doctor will discuss with you whether you should breast-feed considering the benefit to you of your therapy and the benefit to your baby of breast-feeding.
Hvis du tager ABILIFY sammen med anden medicin, skal dosis af ABILIFY eller den anden medicin måske ændres. 
Taking ABILIFY with some medicines may mean the doctor will need to change your dose of ABILIFY or the other medicines.
Et hætteglas indeholder 9,75 mg (1,3 ml) aripiprazol. 
A vial contains 9.75 mg (1.3 mL) aripiprazole.
• Øvrige indholdsstoffer: dinatriumedetat, fructose, glycerin, mælkesyre, methylparahydroxybenzoat (E 218), propylenglycol, propylparahydroxybenzoat (E 216), natriumhydroxid, saccharose, renset vand samt appelsinsmagsstof. 
• The other ingredients are disodium edetate, fructose, glycerin, lactic acid, methyl parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate (E216), sodium hydroxide, sucrose, purified water, and orange flavour.
Maniske episoder ved bipolær lidelse type I: i et 12-ugers, kontrolleret forsøg var forekomsten af EPS 23,5 % for aripiprazol-behandlede patienter og 53,3 % for haloperidol-behandlede patienter. 
Manic episodes in Bipolar I Disorder: in a 12-week controlled trial, the incidence of EPS was 23.5 % for aripiprazole-treated patients and 53.3 % for haloperidol-treated patients.
I et korterevarende, placebo-kontrolleret klinisk forsøg, der involverede 302 unge (13 til 17 år) med skizofreni, var bivirkningsfrekvensen og -typen lig den for voksne undtagen for følgende bivirkninger, der blev rapporteret hyppigere hos unge, der fik aripiprazol end hos voksne, der fik aripiprazol (og hyppigere end med placebo): 
Schizophrenia in adolescents aged 15 years and older In a short-term placebo-controlled clinical trial involving 302 adolescents (13 to 17 years) with schizophrenia, the frequency and type of adverse reactions were similar to those in adults except for the following reactions that were reported more frequently in adolescents receiving aripiprazole than in adults receiving aripiprazole (and more frequently than placebo):
Det er vigtigt, at du fortsætter med at tage ABILIFY i så lang tid, som lægen har sagt, at du skal have det. 
It is important that you carry on taking ABILIFY for as long as your doctor has told you to.
Unge mennesker i alderen 13 år og derover fik bivirkninger, der var sammenlignelige i hyppighed og type af bivirkninger hos voksne, undtagen for træthed, ukontrollerbare, spjættende eller rykkende bevægelser, rastløshed og træthed, der blev observeret med hyppigheden ”meget almindelig” (hos flere end 1 ud af 10 patienter), og mavesmerter i den øverste del af maven, tør mund, øget hjerterytme (puls), vægtstigning, øget appetit, muskeltrækninger, ukontrollerede bevægelser af arme og ben samt svimmelhed, specielt ved skift fra liggende eller siddende til oprejst stilling, hvor hyppigheden var ”almindelig” (flere end 1 ud af 100 patienter). 
Adolescents aged 13 years and older experienced side effects that were similar in frequency and type to those in adults except that sleepiness, uncontrollable twitching or jerking movements, restlessness, and tiredness were very common (greater than 1 in 10 patients) and upper abdominal pain, dry mouth, increased heart rate, weight gain, increased appetite, muscle twitching, uncontrolled movements of the limbs, and feeling dizzy, especially when getting up from a lying or sitting position, were common (greater than 1 in 100 patients).
• tricykliske præparater (fx clomipramin og amitriptylin) til behandling af depressive sindslidelser 
• tricyclic's (such as clomipramine and amitriptyline) used for depressive illness
Hvis du får ABILIFY sammen med anden medicin, skal dosis af ABILIFY eller den anden medicin måske ændres. 
Receiving ABILIFY with some medicines may mean the doctor will need to change your dose of ABILIFY or the other medicines.
Forekomsten af hyperprolaktinæmi eller forhøjet serumprolaktin i aripiprazol-gruppen (0,3 %) svarede til forekomsten i placebo-gruppen (0,2 %). 
The incidence of hyperprolactinaemia or increased serum prolactin in patients treated with aripiprazole (0.3 %) was similar to that of placebo (0.2 %).
Effekt af ABILIFY injektionsvæske, opløsning hos patienter med agitation og adfærdsforstyrrelser er ikke undersøgt i andre sammenhænge end skizofreni og maniske episoder ved bipolær lidelse type I. 
The efficacy of ABILIFY solution for injection in patients with agitation and disturbed behaviours has not been established related to conditions other than schizophrenia and manic episodes in Bipolar I Disorder.
Kontakt lægen, før du tager ABILIFY. 
Talk to your doctor before taking ABILIFY.
I et 26-ugers, placebokontrolleret forsøg med voksne stabiliserede patienter med kronisk skizofreni var oral aripiprazol forbundet med en signifikant større reduktion i tilbagefaldsraten; 34 % i oral aripiprazolgruppen og 57 % i placebo. 
In a 26-week, placebo-controlled trial in adult stabilised patients with chronic schizophrenia, oral aripiprazole had significantly greater reduction in relapse rate, 34 % in oral aripiprazole group and 57 % in placebo.
Hvis du har glemt at tage ABILIFY 
If you forget to take ABILIFY
Ikke almindelig Ikke kendt forstyrrelser 
Not known disorders
Tegn og symptomer på denne tilstand kan især forekomme ved samtidig anvendelse af andre serotonerge lægemidler som f.eks. SSRI/SNRI (selektive serotoningenoptagelseshæmmere/serotonin- og noradrenalingenoptagelseshæmmere) og af lægemidler, der er kendt for at øge aripiprazolkoncentrationen (se pkt. 
Cases of serotonin syndrome have been reported in patients taking aripiprazole, and possible signs and symptoms for this condition can occur especially in cases of concomitant use with other serotonergic medicinal products, such as selective serotonin reuptake inhibitor/selective serotonin noradrenalin reuptake inhibitor (SSRI/SNRI), or with medicinal products that are known to increase aripiprazole concentrations (see section 4.8).
• vægtstigning, 
• weight loss,
ABILIFY 5 mg tabletter Indigotin (E 132) 
ABILIFY 5 mg tablets Indigo carmine aluminium lake (E 132)
• taleforstyrrelse, 
• speech disorder,
Lægen eller sygeplejersken vil indsprøjte den rigtige mængde opløsning i musklen. 
The correct amount of solution will be injected into your muscle by your doctor or nurse.
• nervøsitet, 
• nervousness,
Maniske episoder ved bipolær lidelse type I hos unge i alderen 13 år og ældre Hyppigheden og typen af bivirkninger hos unge med bipolær lidelse type I var de samme som hos voksne med undtagelse af følgende bivirkninger: meget almindelig (≥ 1/10) døsighed (23,0 %), ekstrapyramidale symptomer (18,4 %), akatisi (16,0 %) og træthed (11,8 %); og almindelig (≥ 1/100 til < 1/10) øvre abdominalsmerter, øget hjertefrekvens, vægtstigning, øget appetit, muskeltrækninger og dyskinesi. 
Manic episodes in Bipolar I Disorder in adolescents aged 13 years and older The frequency and type of adverse reactions in adolescents with Bipolar I Disorder were similar to those in adults except for the following reactions: very commonly (≥ 1/10) somnolence (23.0 %), extrapyramidal disorder (18.4 %), akathisia (16.0 %), and fatigue (11.8 %); and commonly (≥ 1/100, < 1/10) abdominal pain upper, heart rate increased, weight increased, increased appetite, muscle twitching, and dyskinesia.
Den orale opløsning indeholder natrium. 
The oral solution contains sodium.
• Øvrige indholdsstoffer: sulfobutylether β-cyclodextrin (SBECD), vinsyre, natriumhydroxid og vand til injektionsvæsker. 
• The other ingredients are sulfobutylether β-cyclodextrin (SBECD), tartaric acid, sodium hydroxide, and water for injections.
• Øvrige indholdsstoffer: lactosemonohydrat, majsstivelse, mikrokrystallinsk cellulose, hydroxypropylcellulose, magnesiumstearat. 
• The other ingredients are lactose monohydrate, maize starch, microcrystalline cellulose, hydroxypropylcellulose and magnesium stearate.
I ét kortvarigt (24-timers) placebokontrolleret forsøg med 291 patienter med bipolær lidelse og agitation samt adfærdsforstyrrelser, var ABILIFY opløsning til injektion forbundet med statistisk signifikante større forbedringer i agitations-/adfærdssymptomerne sammenlignet med placebo og forbedringer svarende til referencearmen med lorazepam. 
In one short-term (24-hour) placebo-controlled trial involving 291 patients with bipolar disorder presenting with agitation and disturbed behaviours, ABILIFY solution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to the reference arm lorazepam.
Åbn pakken og træk folien af blisteren for at frigøre smeltetabletten. 
For single tablet removal, open the package and peel back the foil on the blister to expose the tablet.
Tal med lægen, før du får ABILIFY. 
Talk to your doctor before you are given ABILIFY.
Der er ingen forskel på farmakokinetik for aripiprazol hos raske mandlige og kvindelige forsøgspersoner, ligesom der i en farmakokinetisk populationsanalyse af skizofrene patienter ikke er set påviselig effekt af køn. 
There are no differences in the pharmacokinetics of aripiprazole between healthy male and female subjects nor is there any detectable effect of gender in a population pharmacokinetic analysis in schizophrenic patients.
Indlægsseddel: Information til brugeren ABILIFY 1 mg/ml oral opløsning aripiprazol 
Package leaflet: Information for the user ABILIFY 1 mg/mL oral solution aripiprazole
Parahydroxybenzoater 
Parahydroxybenzoate
Rund og gul, graveret med ”A-009” og ”15” på den ene side. 
Round and yellow, engraved with "A-009" and "15" on one side.
Bør ikke anvendes til patienter med hereditær fructoseintolerans, glucose/galactosemalabsorption og sucrase-isomaltasemangel. 
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
• visse lægemidler mod HIV (fx efavirenz, nevirapin, indinavir eller ritonavir 
• certain medicines to treat HIV infection (such as efavirenz, nevirapine, an protease inhibitors e.g. indinavir, ritonavir)
Der er ialt indberettet cerebrovaskulære bivirkninger hos 1,3 % af de aripiprazol-behandlede patienter i forsøgene sammenlignet med 0,6 % af de placebo-behandlede. 
Overall, 1.3 % of aripiprazole-treated patients reported cerebrovascular adverse reactions compared with 0.6 % of placebo-treated patients in these trials.
Agitation ved skizofreni og bipolær lidelse type I med ABILIFY injektionsvæske, opløsning I 2 korterevarende (24-timers) placebokontrollerede forsøg med 554 skizofrene, voksne patienter med agitation og adfærdsforstyrrelser, var ABILIFY injektionsvæske, opløsning forbundet med statistisk signifikant større forbedringer i agitation/adfærdssymptomer sammenlignet med placebo og svarende til haloperidol. 
Agitation in schizophrenia and Bipolar I Disorder with ABILIFY solution for injection In two short- term (24-hour) placebo-controlled trials involving 554 schizophrenic adult patients presenting with agitation and disturbed behaviours, ABILIFYsolution for injection was associated with statistically significant greater improvements in agitation/behavioural symptoms compared to placebo and was similar to haloperidol.
AUC og Cmax for dehydroaripiprazol øgedes med henholdsvis 77 % og 43 %. 
The AUC and Cmax of dehydroaripiprazole increased by 77 % and 43 %, respectively.
Lægen kan dog have ordineret en lavere eller højere dosis, op til højst 30 mg én gang dagligt. 
However your doctor may prescribe a lower or higher dose to a maximum of 30 mg once a day.
Der er dog i et forsøg med intramuskulære enkeltdoser af aripiprazol (dosis 15 mg) til raske frivillige, administreret samtidig med intramuskulært lorazepam (dosis 2 mg), set større grad af ortostatisk hypotension ved kombinationen end for lorazepam alene. 
However, in a single-dose, intramuscular study of aripiprazole (dose 15 mg) in healthy subjects, administered simultaneously with intramuscular lorazepam (dose 2 mg), the orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone.
I et 26ugers, kontrolleret, dobbeltblindt, multinationalt forsøg med olanzapin til behandling af skizofreni, som inkluderede 314 voksne patienter, og hvor det primære endepunkt var vægtstigning, fandtes signifikant færre patienter at have 7 % eller yderligere vægtstigning i forhold til baseline (dvs en stigning på mindst 5,6 kg for en middel-baselinevægt på ∼80,5 kg) med oral aripripazol (n = 18 eller 13 % af de evaluérbare patienter) sammenlignet med oral olanzapin (n = 45 eller 33 % af de evaluérbare patienter). 
In a 26-week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on oral aripiprazole (n = 18, or 13 % of evaluable patients), compared to oral olanzapine (n = 45, or 33 % of evaluable patients).
I et 26-ugers, kontrolleret, dobbeltblindt, multinationalt forsøg med olanzapin til behandling af skizofreni, som inkluderede 314 voksne patienter, og hvor det primære endepunkt var vægtstigning, fandtes signifikant færre patienter at have 7 % eller yderligere vægtstigning i forhold til baseline (dvs en stigning på mindst 5,6 kg for en middel-baselinevægt på ∼80,5 kg) med aripripazol (n = 18 eller 13 % af de evaluérbare patienter) sammenlignet med olanzapin (n = 45 eller 33 % af de evaluérbare patienter). 
In a 26-week, olanzapine-controlled, double-blind, multi-national study of schizophrenia which included 314 adult patients and where the primary endpoint was weight gain, significantly less patients had at least 7 % weight gain over baseline (i.e. a gain of at least 5.6 kg for a mean baseline weight of ~80.5 kg) on aripiprazole (n = 18, or 13 % of evaluable patients), compared to olanzapine (n = 45, or 33 % of evaluable patients).
ABILIFY gives når behandling med tabletter, smeltetabletter eller oral opløsning ikke er hensigtsmæssigt. 
ABILIFY is given when treatment with oral formulations is not appropriate.
Et hætteglas giver 9,75 mg per 1,3 ml. 
A vial provides 9.75 mg in 1.3 mL.
ABILIFY injektionsvæske, opløsning havde ingen effekt på farmakokinetik af lorazepam injektionsvæske, opløsning ved samtidig administration. 
The administration of ABILIFY solution for injection had no effect on the pharmacokinetics of lorazepam solution for injection when administered concomitantly.
ABILIFY 1 mg/ml oral opløsning 
ABILIFY 1 mg/mL oral solution
Aggressivitet 
Aggression
Bivirkningerne er opstillet efter systemorganklasse og hyppighed: meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1.000 til < 1/100), sjælden (≥ 1/10.000 til 
All ADRs are listed by system organ class and frequency; very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Patienter med ADHD (hyperaktiv opmærksomhedsforstyrrelse) som co-morbiditet På trods af den høje hyppighed af co-morbiditet med bipolær lidelse type I og ADHD, foreligger der meget begrænsede sikkerhedsdata for samtidig anvendelse af aripiprazol og stimulantia. 
Patients with attention deficit hyperactivity disorder (ADHD) comorbidity Despite the high comorbidity frequency of Bipolar I Disorder and ADHD, very limited safety data are available on concomitant use of aripiprazole and stimulants; therefore, extreme caution should be taken when these medicinal products are co-administered.
Propylparahydroxybenzoat (E 216) 
Propyl parahydroxybenzoate (E 216) Sodium hydroxide
Lorazepam injektionsvæske, opløsning havde ingen effekt på farmakokinetik af ABILIFY injektionsvæske, opløsning ved samtidig administration. 
The administration of lorazepam solution for injection had no effect on the pharmacokinetics of ABILIFY solution for injection when administered concomitantly.
Rund og lyserød, graveret med ”A-011” og ”30” på den ene side. 
Round and pink, engraved with "A-011" and "30" on one side.
• kramper, 
• trembling,
• hjerte-kar-sygdom, hjerte-kar-sygdom i familien, slagtilfælde eller mini-slagtilfælde, unormalt blodtryk 
• cardiovascular diseases (diseases of the heart and circulation), family history of cardiovascular disease, stroke or "mini" stroke, abnormal blood pressure
Den orale opløsning må dog ikke fortyndes med andre væsker eller blandes med mad før indtagelse. 
However, the oral solution should not be diluted with other liquids or mixed with any food prior to administration.
AUC og Cmax for dehydroaripiprazol, den aktive metabolit, reduceredes med henholdsvis 32 % og 47 %. 
The AUC and Cmax of dehydroaripiprazole, the active metabolite, decreased by 32 % and 47 %, respectively.
Nedsat nyrefunktion Dosisjustering til patienter med nedsat nyrefunktion er ikke påkrævet. 
Renal impairment No dosage adjustment is required in patients with renal impairment.
Smeltetabletten kan også opløses i vand og derefter drikkes. 
Alternatively, disperse the tablet in water and drink the resulting suspension.
Dosisjustering til patienter med mild til moderat leverinsufficiens er ikke påkrævet. 
No dosage adjustment is required for patients with mild to moderate hepatic impairment.
Forhøjet alanin-aminotransferase Forhøjet aspartat-aminotransferase Forhøjet gammaglutamyltransferase Forhøjet alkalinfosfatase QT-forlængelse 
Aspartate Aminotransferase increased
I den længerevarende 26-ugers vedligeholdelsesfase i et placebokontrolleret forsøg var forekomsten af EPS 18,2 % for aripiprazol-behandlede patienter og 15,7 % for placebo-behandlede patienter. 
In the long-term 26-week maintenance phase of a placebo-controlled trial, the incidence of EPS was 18.2 % for aripiprazole-treated patients and 15.7 % for placebo-treated patients.
Leversvigt Hepatitis Gulsot 
Hepatic failure Hepatitis Jaundice
ABILIFY 5 mg tabletter ABILIFY 10 mg tabletter ABILIFY 15 mg tabletter ABILIFY 30 mg tabletter 
ABILIFY 5 mg tablets ABILIFY 10 mg tablets ABILIFY 15 mg tablets ABILIFY 30 mg tablets
Methylparahydroxybenzoat (E 218) Propylenglykol 
Methyl parahydroxybenzoate (E 218) Propylene glycol
4.2) Aripiprazol blev undersøgt hos patienter i aldersgruppen 6 til 17 år i to 8-ugers, placebokontrollerede forsøg [én fleksibel dosis (2 mg/dag til 15 mg/dag) og én fast dosis (5 mg/dag, 10 mg/dag eller 15 mg/dag)] og i et 52-ugers åbent forsøg. 
Irritability associated with autistic disorder in paediatric patients (see section 4.2) Aripiprazole was studied in patients aged 6 to 17 years in two 8-week, placebo-controlled trials [one flexible-dose (2 mg/day to 15 mg/day) and one fixed-dose (5 mg/day, 10 mg/day, or 15 mg/day)] and in one 52-week open-label trial.
Hvis der fremkommer symptomer på tardiv dyskinesi hos en patient, der behandles med aripiprazol, skal dosisreduktion eller behandlingsafbrydelse overvejes (se pkt. 
If signs and symptoms of tardive dyskinesia appear in a patient on aripiprazole, dose reduction or discontinuation should be considered (see section 4.8).
Maniske episoder ved bipolær lidelse type I: Den anbefalede startdosis for ABILIFY er 15 mg administreret som en enkelt daglig dosis, uden hensyntagen til måltider, som enkeltstofbehandling eller kombinationsbehandling (se pkt. 
Manic episodes in Bipolar I Disorder: the recommended starting dose for ABILIFY is 15 mg administered on a once-a-day schedule without regard to meals as monotherapy or combination therapy (see section 5.1).
I betragtning af behandlingseffektens størrelsesorden sammenlignet med den store placeboeffekt og de uklare virkninger med hensyn til psykosociale funktioner er den kliniske relevans af virkningsresultaterne i disse to kortvarige studier ikke klarlagt. 
In both of these short-term trials, the clinical relevance of the efficacy findings has not been established, considering the magnitude of treatment effect compared to the large placebo effect and the unclear effects regarding psycho-social functioning.
ABILIFY 1 mg/ml oral opløsning aripiprazol 
ABILIFY 1 mg/mL oral solution aripiprazole
Det skal du vide, før du begynder at tage ABILIFY Tag ikke ABILIFY 
What you need to know before you take ABILIFY Do not take ABILIFY
ABILIFY indeholder lactose 
ABILIFY contains lactose